Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report released on Thursday. The brokerage issued a sell rating on the stock.

A number of other analysts have also issued reports on CANF. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, February 18th.

Can-Fite BioPharma Price Performance

Shares of NYSE CANF opened at $1.76 on Thursday. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69. The company has a market capitalization of $6.23 million, a price-to-earnings ratio of -0.98 and a beta of 1.33. The business has a 50-day moving average of $1.57 and a 200-day moving average of $1.95.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers grew its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.